Immix Biopharma — All eyes on NEXICART-2
Immix’s FY24 results summarize a period of focus on its lead CAR-T asset, NXC-201, which is being developed for amyloid light chain amyloidosis....
389 Views
Immix Biopharma — All eyes on NEXICART-2
Immix’s FY24 results summarize a period of focus on its lead CAR-T asset, NXC-201, which is being developed for amyloid light chain amyloidosis....
322 Views
Immix Biopharma — NXC-201 receives FDA RMAT designation
Immix Biopharma has been granted a Regenerative Medicine Advanced Therapy (RMAT) designation by the US Food and Drug Administration (FDA) for the...
251 Views
Immix Biopharma - US CAR-T trial progresses to dose expansion
Immix Biopharma’s US-based NEXICART-2 trial continues to make steady progress through the clinic, with the company reporting that the trial has...
469 Views
Immix Biopharma - Full steam ahead with US CAR-T trial
Immix Biopharma’s second quarter was headlined by intensified clinical activity for lead CAR-T asset NXC-201 (targeting amyloid light chain...
312 Views